Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research
More News: Cancer & Oncology | China Health | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Lymphoma | Men | Myeloma | Nilotinib | Study | Tasigna